---
document_datetime: 2024-09-03 12:43:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/phesgo-epar-all-authorised-presentations_en.pdf
document_name: phesgo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7465212
conversion_datetime: 2025-12-23 03:57:11.676341
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength         | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/20/1497/001 | Phesgo            | 1200 mg / 600 mg | Solution for injection | Subcutaneous use          | vial (glass)          | 15 ml                     | 1 vial      |
| EU/1/20/1497/002 | Phesgo            | 600 mg / 600 mg  | Solution for injection | Subcutaneous use          | vial (glass)          | 10 ml                     | 1 vial      |